Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331

Leonard A. Mattano,Meenakshi Devidas,Kelly W. Maloney,Cindy Wang,Alison M. Friedmann,Patrick J. Buckley,Michael J. Borowitz,Andrew J. Carroll,Julie M. Gastier-Foster,Nyla A. Heerema,Nina S. Kadan-Lottick,Yousif Matloub,David T. Marshall,Linda C. Stork,Mignon L. Loh,Elizabeth A. Raetz,Brent L. Wood,Stephen P. Hunger,William L. Carroll,Naomi J. Winick

Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331

2021

PURPOSEChildren's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a ...

Keywords:

Internal medicine
Text mining
Oncology
Medicine
Pegaspargase
MEDLINE
group trial
B-cell acute lymphoblastic leukemia
etv6 runx1
Cog
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations